Cargando…

Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma

The aim of the present study was to compare the effectiveness of transarterial chemoembolization (TACE), TACE combined with Jie-du granules (JD), and TACE combined with sorafenib (SOR) for treating patients with unresectable hepatocellular carcinoma (HCC). For this purpose, we conducted a retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hetong, Zhai, Xiaofeng, Chen, Zhe, Wan, Xuying, Chen, Lanyu, Shen, Feng, Ling, Changquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542181/
https://www.ncbi.nlm.nih.gov/pubmed/28423370
http://dx.doi.org/10.18632/oncotarget.16804
_version_ 1783254936053612544
author Zhao, Hetong
Zhai, Xiaofeng
Chen, Zhe
Wan, Xuying
Chen, Lanyu
Shen, Feng
Ling, Changquan
author_facet Zhao, Hetong
Zhai, Xiaofeng
Chen, Zhe
Wan, Xuying
Chen, Lanyu
Shen, Feng
Ling, Changquan
author_sort Zhao, Hetong
collection PubMed
description The aim of the present study was to compare the effectiveness of transarterial chemoembolization (TACE), TACE combined with Jie-du granules (JD), and TACE combined with sorafenib (SOR) for treating patients with unresectable hepatocellular carcinoma (HCC). For this purpose, we conducted a retrospective analysis of data from 266 consecutive patients with unresectable HCC who underwent TACE treatment at the Shanghai Hospital and Eastern Hepatic Surgery Hospital between Jan 2009 and Dec 2010. We prospectively analyzed patient survival and progression times as well as independent predictors, within a follow-up period of 86 months. Patients were divided into TACE-JD (n = 75), TACE-SOR (n = 124) and TACE (n = 67) groups. Median overall survival (OS) times being: TACE-JD, 21.43 months; TACE-SOR, 23.23 months; TACE, 13.97 months (TACE-SOR vs TACE, P < 0.001; TACE-SOR vs TACE-JD, P = 0.852; TACE-JD vs TACE, P < 0.001). The median times to progression (TTP) were as follows: TACE-JD, 8.67 months; TACE-SOR, 5.37 months; TACE, 4.57 months (TACE-SOR vs TACE, P = 0.479; TACE-SOR vs TACE-JD, P < 0.001; TACE-JD vs TACE, P < 0.001). Independent predictors of OS were treatment allocation, Child-Pugh class large tumor, albumin and extrahepatic metastasis. These findings show that patients with unresectable HCC who were administered TACE-JD survived significantly longer compared with those administered TACE or TACE-SOR.
format Online
Article
Text
id pubmed-5542181
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55421812017-08-07 Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma Zhao, Hetong Zhai, Xiaofeng Chen, Zhe Wan, Xuying Chen, Lanyu Shen, Feng Ling, Changquan Oncotarget Research Paper The aim of the present study was to compare the effectiveness of transarterial chemoembolization (TACE), TACE combined with Jie-du granules (JD), and TACE combined with sorafenib (SOR) for treating patients with unresectable hepatocellular carcinoma (HCC). For this purpose, we conducted a retrospective analysis of data from 266 consecutive patients with unresectable HCC who underwent TACE treatment at the Shanghai Hospital and Eastern Hepatic Surgery Hospital between Jan 2009 and Dec 2010. We prospectively analyzed patient survival and progression times as well as independent predictors, within a follow-up period of 86 months. Patients were divided into TACE-JD (n = 75), TACE-SOR (n = 124) and TACE (n = 67) groups. Median overall survival (OS) times being: TACE-JD, 21.43 months; TACE-SOR, 23.23 months; TACE, 13.97 months (TACE-SOR vs TACE, P < 0.001; TACE-SOR vs TACE-JD, P = 0.852; TACE-JD vs TACE, P < 0.001). The median times to progression (TTP) were as follows: TACE-JD, 8.67 months; TACE-SOR, 5.37 months; TACE, 4.57 months (TACE-SOR vs TACE, P = 0.479; TACE-SOR vs TACE-JD, P < 0.001; TACE-JD vs TACE, P < 0.001). Independent predictors of OS were treatment allocation, Child-Pugh class large tumor, albumin and extrahepatic metastasis. These findings show that patients with unresectable HCC who were administered TACE-JD survived significantly longer compared with those administered TACE or TACE-SOR. Impact Journals LLC 2017-04-03 /pmc/articles/PMC5542181/ /pubmed/28423370 http://dx.doi.org/10.18632/oncotarget.16804 Text en Copyright: © 2017 Zhao et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Zhao, Hetong
Zhai, Xiaofeng
Chen, Zhe
Wan, Xuying
Chen, Lanyu
Shen, Feng
Ling, Changquan
Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma
title Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma
title_full Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma
title_fullStr Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma
title_full_unstemmed Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma
title_short Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma
title_sort transarterial chemoembolization combined with jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542181/
https://www.ncbi.nlm.nih.gov/pubmed/28423370
http://dx.doi.org/10.18632/oncotarget.16804
work_keys_str_mv AT zhaohetong transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma
AT zhaixiaofeng transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma
AT chenzhe transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma
AT wanxuying transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma
AT chenlanyu transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma
AT shenfeng transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma
AT lingchangquan transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma